ASBMR 2015

October 2015 - Entera presents the "Oral PTH (1-34) in the Treatment of Hypoparathyroidism" for its hypoparathyroidism drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Seattle, Washington. Primary hypoparathyroidism (PHP) is a hormone deficiency for which no oral replacement therapy is currently available. Oral PTH administration may allow for more flexibility in providing an adequate therapeutic dose, for achievement of normocalemia and normophosphatemia in patients with varied severity of hormone deficiency and response to therapy. Entera presented the results of its Phase 2a clinical study.
Despite not having an optimization period and the relatively short treatment duration (4 months) Entera Bio’s Oral PTH has shown clear safety and efficacy.

pdfSee poster